- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cognition Therapeutics Inc (CGTX)
Cognition Therapeutics Inc stock price live, this page displays NASDAQ CGTX stock exchange data. View the CGTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cognition Therapeutics Inc real time stock price chart below.
What Is the Cognition Therapeutics Inc Stock Price Today?
The Cognition Therapeutics Inc stock price today is 1.010.
What Is the Stock Symbol for Cognition Therapeutics Inc?
The stock symbol for Cognition Therapeutics Inc is "CGTX."
What Stock Exchange Does Cognition Therapeutics Inc Trade On?
Cognition Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Cognition Therapeutics Inc a Good Stock to Buy?
Determining whether Cognition Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CGTX quote. (ISIN: US19243B1026)
What Is the Cognition Therapeutics Inc Stock Price Today?
The Cognition Therapeutics Inc stock price today is 1.010.
What Is the Stock Symbol for Cognition Therapeutics Inc?
The stock symbol for Cognition Therapeutics Inc is "CGTX."
What Stock Exchange Does Cognition Therapeutics Inc Trade On?
Cognition Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Cognition Therapeutics Inc a Good Stock to Buy?
Determining whether Cognition Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CGTX quote. (ISIN: US19243B1026)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.000
1.050
52 wk Range
0.550
3.830
CGTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.0001.050
52 wk Range
0.5503.830
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CGTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
3.333
Upside
+230.03%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 3.333
(+230.03% Upside)
Cognition Therapeutics Inc Earnings Call Summary for Q4/2025
- Cognition Therapeutics reduced net loss 30.9% YoY to $23.5M vs $34.0M in 2024; cash runway extends through Q2 2027 with $72.7M liquidity.
- Lead candidate Zervimesine showed promising results in DLB trials; company pivoting strategy to prioritize DLB psychosis indication.
- FDA regulatory guidance for DLB psychosis expected mid-2026; plans to advance Alzheimer's program using biomarker enrichment strategies.
- Stock declined 0.81% in pre-market to $1.101 despite improved financials, reflecting investor caution near 52-week low of $0.222.
- Company achieved operational efficiency through cost-cutting post-trial completion; faces challenges securing funding and navigating competitive market.
Last Updated: 2026-03-26, 09:10 a/m
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.04 / -0.05
Revenue / Forecast
-- / --
Compare CGTX to Peers and Sector
Metrics to compare | CGTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCGTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.7x | −14.6x | −0.4x | |
PEG Ratio | −0.08 | −0.13 | 0.00 | |
Price/Book | 2.9x | 7.5x | 2.6x | |
Price / LTM Sales | - | 12.9x | 3.1x | |
Upside (Analyst Target) | 197.0% | 69.0% | 47.9% | |
Fair Value Upside | Unlock | −9.1% | 6.3% | Unlock |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer’s disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Cognition Therapeutics (CGTX) Stock Price Today?
The Cognition Therapeutics stock price today is 1.010 USD.
What Stock Exchange Does Cognition Therapeutics Trade On?
Cognition Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Cognition Therapeutics?
The stock symbol for Cognition Therapeutics is "CGTX."
What Is the Cognition Therapeutics Market Cap?
As of today, Cognition Therapeutics market cap is 96.040M USD.
What Is Cognition Therapeutics's Earnings Per Share (TTM)?
The Cognition Therapeutics EPS (TTM) is -0.194.
When Is the Next Cognition Therapeutics Earnings Date?
Cognition Therapeutics will release its next earnings report on Nov 18, 2026.
From a Technical Analysis Perspective, Is CGTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Cognition Therapeutics Stock Split?
Cognition Therapeutics has split 0 times.
How Many Employees Does Cognition Therapeutics Have?
Cognition Therapeutics has 14 employees.
What is the current trading status of Cognition Therapeutics (CGTX)?
As of Aug 17, 2026, Cognition Therapeutics (CGTX) is trading at a price of 1.010 USD, with a previous close of 1.010 USD. The stock has fluctuated within a day range of 1.000 USD to 1.050 USD, while its 52-week range spans from 0.550 USD to 3.830 USD.
What Is Cognition Therapeutics (CGTX) Price Target According to Analysts?
The average 12-month price target for Cognition Therapeutics is 3.333 USD, with a high estimate of 4 USD and a low estimate of 3 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +230.03% Upside potential.
What Is the CGTX Premarket Price?
CGTX's last pre-market stock price is 1.000 USD. The pre-market share volume is 70.000, and the stock has decreased by -0.010, or -0.990%.
What Is the CGTX After Hours Price?
CGTX's last after hours stock price is 1.050 USD, the stock has decreased by 0.040, or 3.960%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.